Our team consists of world class clinicians, clinical researchers, research scientists, and software engineers working together to develop a novel pharmacogenomic test that can improve the clinical management of patients.
The members of this unique team bring a diverse set of experience and skills, a record of research achievements and substantial national reputations in their fields. The team possesses the necessary clinical, molecular bioinformatics, technology, operational and regulatory expertise, and extensive networks to successfully develop and bring to market the medical device.
Dr Svetlana Baltic has over 20 years of experience in molecular mechanisms underpinning gene regulation and its relevance to disease and future treatments. She has extensive expertise in broad range of genomic applications in biotechnology and development and commercialisation of medical devices.
Dr Suzanna Lindsey-Temple has over 20 years of experience in medical research largely in the area of genetics including previously as Research Assistant Professor at the University of Western Australia. She is a Fellow of the Royal Australasian College of Physicians – Paediatrics and Child Health who sub-specialised and works as a Clinical Geneticist in Sydney.
Chair of the Gene S Business Advisory Board advises and manages all strategic and business aspects of the company, building and maintaining respected relationships with key stakeholders in both the public and private sectors.
Chief Financial Officer helps shape corporate strategy and provide financial and commercial advice to identify opportunities that deliver sustainable growth and ensure statutory and regulatory compliance.
Head of Operations and QA/RA helps with the Operations (Laboratory, Manufacturing/Process Development) and Quality Assurance and Regulatory Affairs.
David provides strategic sales and marketing advice to the GeneS founders on how to commercialise and scale a leading medical device brand.
Laura has 25 years of experience in academia, biotech and pharmaceutical industries. She is an expert in drug discovery, development, commercialisation and intellectual property management and investment. Laura is currently responsible for the business development and external partnerships strategy.
